NUSATRIP Inc. Material Event - Investor Update

NUSATRIP Inc. faces a significant challenge: its stock trading has been halted by Nasdaq due to ongoing regulatory inquiries. This update provides a clear overview of the situation for investors.

---

1. What Happened: Trading Halted Due to Regulatory Inquiries

NUSATRIP Inc. announced that Nasdaq halted trading of its common stock on February 3, 2026, and the suspension continues. This halt is a direct result of ongoing inquiries and requests for information from both Nasdaq and the U.S. Securities and Exchange Commission (SEC). NUSATRIP has not disclosed the specific nature of these inquiries. However, regulators typically halt trading due to concerns about a company's financial reporting accuracy, compliance with listing rules, or broader market integrity. This means investors currently cannot buy or sell NUSATRIP shares on Nasdaq.

2. Timeline of Events

The situation developed over several months:

• October 9, 2025: Nasdaq initiated the first request for information.
• October 14, 2025: NUSATRIP provided its initial response.
• November 17, 2025: NUSATRIP submitted further responses to follow-up questions from Nasdaq.
• December 22, 2025: The SEC issued its own request for documents.
• January 20, 2026: NUSATRIP responded to the SEC's request.
• February 3, 2026: The company filed an update confirming the continued trading halt.

3. Why This Is Happening: Unresolved Regulatory Concerns

Stock exchanges and regulators like Nasdaq and the SEC do not halt trading or demand extensive documentation without serious underlying concerns. While NUSATRIP has not publicly detailed the "outstanding matters," these inquiries often involve:

• Financial Reporting Irregularities: Questions about the accuracy of past financial statements, revenue recognition, or accounting practices.
• Compliance Issues: Potential violations of Nasdaq listing rules or SEC regulations.
• Market Integrity: Concerns about trading activity, insider transactions, or disclosure practices.

NUSATRIP has stated its full cooperation with both Nasdaq and the SEC. However, the prolonged suspension of trading indicates that the issues are complex and have not yet been satisfactorily resolved. The severity of these inquiries could range from minor disclosure deficiencies to more significant accounting or legal problems.

4. General Impact: Significant Investor and Business Implications

The trading halt carries substantial implications for both investors and the company:

• Inability to Trade Shares: Shareholders cannot sell their NUSATRIP stock on Nasdaq, effectively locking up their investment. This prevents them from reacting to new information or managing their portfolio. New investors also cannot buy shares through the exchange.
• Serious Risks: Extensive regulatory scrutiny suggests significant underlying problems that could lead to severe consequences, including delisting from Nasdaq.
• Reputational Damage: Being under a trading halt and regulatory investigation can severely damage a company's reputation, impacting investor confidence, its ability to attract and retain talent, and potentially its relationships with business partners and lenders.
• Business Operations Under Scrutiny: NUSATRIP states that its daily business operations remain normal and unaffected by the suspension. However, intense regulatory focus can divert management attention and resources, potentially impacting long-term strategy and employee morale, even if day-to-day customer service continues.

5. Financial Impact

The ongoing regulatory inquiries and trading halt will likely have several financial implications for NUSATRIP Inc.:

• Increased Costs: The company will likely face higher legal and accounting costs as it responds to ongoing regulatory investigations from Nasdaq and the SEC.
• Hindered Capital Raising: A prolonged trading halt and regulatory scrutiny can significantly hinder NUSATRIP's ability to raise capital through stock offerings, secure new debt, or pursue strategic initiatives like mergers and acquisitions.
• Potential Penalties and Restatements: Depending on investigation findings, NUSATRIP could face significant financial penalties from regulators. The company may also need to restate past financial results, which carries further financial and reputational consequences.
• Impact on Shareholder Value: The inability to trade the stock and the uncertainty surrounding the investigations could significantly reduce shareholder value, especially if the stock is delisted or adverse findings are announced.

6. Who Is Affected?

• NUSATRIP Shareholders: This group faces the most direct impact, experiencing an inability to trade their shares and significant uncertainty about their investment's value and future, with potential for substantial loss.
• NUSATRIP Management and Employees: Management is heavily engaged in responding to regulatory demands, diverting focus from core business. Employees may experience increased uncertainty.
• NUSATRIP Customers: While the company claims operations are normal, any long-term financial or reputational damage could indirectly affect service quality or offerings.
• Business Partners and Lenders: May re-evaluate their relationships and terms with NUSATRIP due to increased risk.

7. What Happens Next: Potential Outcomes and Unpredictable Timeline

NUSATRIP has committed to providing further updates. Investors should understand the range of potential outcomes:

• Resumption of Trading: In the best-case scenario, NUSATRIP resolves the outstanding issues to Nasdaq's and the SEC's satisfaction, and Nasdaq lifts the trading halt. This could happen with or without additional disclosures or corrective actions.
• Delisting from Nasdaq: If the company fails to meet Nasdaq's listing requirements or resolve regulatory concerns, its stock could be delisted. This would likely shift trading to less regulated, less transparent over-the-counter (OTC) markets, potentially causing a significant decline in share value.
• Financial Penalties and Restatements: The SEC could impose fines, and the company might be required to restate past financial results, which can further erode investor confidence.
• Management Changes: Depending on the findings, changes in executive leadership or the board of directors could occur.

The timeline for resolving such regulatory matters is highly unpredictable, often spanning several months or even longer, depending on the complexity of the issues.

8. Key Takeaways for Investors

• Your Shares Are Untradable on Nasdaq: Understand that you cannot currently buy or sell NUSATRIP shares on the primary exchange.
• High Uncertainty and Risk of Loss: The situation is highly uncertain, with no clear timeline or guaranteed positive outcome. Be prepared for the possibility of significant, or even permanent, loss of investment, especially if delisting occurs.
• Review Past Financials: Consider reviewing NUSATRIP's past financial statements and disclosures for any potential anomalies or areas that might be under regulatory scrutiny.
• Re-evaluate Your Investment Thesis: Assess how this prolonged trading halt and regulatory investigation impact your original reasons for investing in NUSATRIP.
• Rely on Official Updates: Disregard rumors and wait for official statements from NUSATRIP, Nasdaq, or the SEC.
• Consult a Financial Advisor: Given the complexity and high risk, consider seeking advice from a qualified financial professional.